Mylan settles with Warner Chilcott over generic version of Femcon Fe
PITTSBURGH — Generic drug maker Mylan has settled with Warner Chilcott in a case concerning an oral contraceptive.
Mylan said Wednesday that it and Famy Care had entered into an agreement with Warner Chilcott resolving a lawsuit over Femcon Fe (norethindrone and ethinyl estradiol chewable tablets, ferrous fumarate tablets).
Under the settlement, the litigation has been dismissed, and Mylan can begin marketing and selling a generic version of the drug once it receives approval from the Food and Drug Administration. Additional details of the settlement are confidential, Mylan said.
Mylan’s Matrix Labs subsidiary gets name change
PITTSBURGH — Mylan’s India-based subsidiary is changing its name, Mylan said Wednesday.
The generic drug maker announced that Matrix Labs, based in Hyderabad, India, had formally changed its name to Mylan Labs.
"We are pleased to complete the name change from Matrix to a Mylan company and are excited to operate in India under one powerful brand," Mylan chairman and CEO Robert Coury said.
Mylan acquired Matrix in 2006.
Concepts in Health defends MidNite Sleep Remedy patent
BLAUVELT, N.Y. — Concepts in Health on Wednesday reported it successfully has defended its MidNite Sleep Remedy patent from possible infringement by Contract Pharmacal, which had been manufacturing a store-brand version.
According to Concepts, Contract Pharmacal agreed to discontinue manufacturing and selling CVS Natural Sleep Aid or any substantially similar product. Additionally, CPC will not challenge the validity or enforceability of the MidNite patent (U.S. Patent 6,703,412).
“We are deeply gratified by the outcome of this settlement,” stated Holly Rosenthal, Concepts president. “We will continue to vigorously protect our intellectual property at whatever cost.”
Under the terms of the agreement, CPC did not admit liability for infringement of, or to the validity or enforceability of, the ‘412 patent. Financial and other terms of the settlement were not disclosed.